Grifols

Grifols to acquire Novartis blood transfusion diagnostics unit for $1.675 billion

Monday, November 11, 2013 04:42 PM

Novartis announced a definitive agreement to divest its blood transfusion diagnostics unit to Grifols for $1.675 billion. This transaction, requiring customary regulatory approvals, is expected to be completed in the first half of 2014.

More... »


Grifols, Aradigm sign licensing agreement to develop, commercialize Pulmaquin

Wednesday, May 22, 2013 12:14 PM

Grifols, a global healthcare company, and Aradigm, an emerging specialty pharmaceutical company focused severe respiratory diseases, have signed an exclusive worldwide license for Aradigm's proprietary formulations of inhaled ciprofloxacin (Pulmaquin and Lipoquin) for the treatment of severe respiratory diseases, including non-cystic fibrosis bronchiectasis (BE). Aradigm has completed phase IIb clinical trials in BE patients with Pulmaquin and Lipoquin.

More... »


Grifols initiates safety study of inhaled alpha1-proteinase inhibitor for CF

Thursday, July 19, 2012 01:18 PM

Grifols, a global healthcare company based in Barcelona, Spain, plans to initiate a safety trial of a novel, inhaled formulation of alpha1-proteinase inhibitor [human] later this year.  In April, the FDA granted orphan drug designation for Grifols' inhaled alpha1 formulation as a treatment for cystic fibrosis, an inherited disease that can cause life-threatening lung infections. Orphan drug designation is granted to encourage the development of treatments that prevent, diagnose or treat rare diseases that affect fewer than 200,000 people per year in the U.S.

More... »

CenterWatch Data Library
CWWeekly

January 26

2015 CRO outlook: M&As, IPOs, strategic partnerships and increased eClinical outsourcing expected to continue

IOM, industry stakeholders propose standards, guidelines for open sharing of clinical trial data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs